ReviewEClinicalMedicine2021
Extrapulmonary sarcoidosis with a focus on cardiac, nervous system, and ocular involvement.
Review in EClinicalMedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 28 citations in OpenAlex.
- Neurosarcoidosis as an elusive mimicker of infection and neoplasia: a case report.Journal of neurology · 2026Article
- New Therapies for Sarcoidosis: Molecular and Pathophysiological Basis.International journal of molecular sciences · 2026Review
- Uncovering Sex and Gender Differences in Sarcoidosis: A Systematic Review of Current Evidence.Journal of personalized medicine · 2026Review
- Diagnosis and treatment of sarcoidosis based on immunological etiology and mechanisms.Frontiers in medicine · 2026Review
- Scoping out sarcoidosis: the evolving role of bronchoscopy.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Concomitant Neurosarcoidosis and Cardiac Sarcoidosis: A Peculiar Path to Diagnosis.The American journal of case reports · 2025Article
- The ACE/lymphocyte ratio and CONUT score: Key predictors of extrapulmonary involvement and recurrence in sarcoidosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- A Case Report: The Utility of Multimodality Imaging in the Diagnosis of Cardiac Sarcoidosis-Has It Surpassed the Need for a Biopsy?Reports (MDPI) · 2025Article
- Neurosarcoidosis: An under-diagnosed cause of myelopathy.Journal of family medicine and primary care · 2024Article
- Principal component analysis of clinical characteristics of pulmonary sarcoidosis with or without extrapulmonary lesions: a single-center observational study in Japan.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2024Article
- Cardiac Involvement in Neurosarcoidosis: A Single-Center InvestigationNeurology(R) neuroimmunology & neuroinflammation · 2024Article
- Diagnosis of systemic sarcoidosis in a patient with bilateral granulomatous pan-uveitis: a case report.Annals of medicine and surgery (2012) · 2024Article
- Casual effects of telomere length on sarcoidosis: a bidirectional Mendelian randomization analysis.Frontiers in medicine · 2024Article
- Review
- Association between sarcoidosis and cardiovascular Outcomes: A systematic review and Meta-analysis.International journal of cardiology. Heart & vasculature · 2022Article
- Sarcoid Uveitis: An Intriguing Challenger.Medicina (Kaunas, Lithuania) · 2022Review
- Article
- Epidemiology, clinical presentation, treatment, and outcome of neurosarcoidosis: A mono-centric retrospective study and literature review.Frontiers in neurology · 2022Article
- Study of CT-Guided Localization in Pulmonary Nodule Resection.Applied bionics and biomechanics · 2022Article
- Epidemiology, Pathogenesis, and Diagnosis of Cardiac Sarcoidosis.Methodist DeBakey cardiovascular journal · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Sarcoidosis is a poorly understood granulomatous disease that involves the lungs and/or intrathoracic lymph nodes in more than 90% of cases. Although pulmonary sarcoidosis is the leading cause of mortality in this disease, this review focuses on three sites of extrapulmonary involvement (heart, nervous system, and eyes), since involvement of any of these sites can be catastrophic, leading to death, debilitation, or blindness. Patients with cardiac, ocular and neurosarcoidosis necessitate a multidisciplinary approach with careful and long-term follow-up. Prompt diagnosis with imaging and/or biopsy and treatment is required to avoid irreversible damage. Corticosteroids are the mainstay of therapy and are often associated with rapid and durable remissions. Immunosuppressive or biologic agents are reserved for patients failing or experiencing side effects from steroids. Managing sarcoidosis requires vigilance, judgement, and awareness of the vagaries of this fascinating disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.